Lacosamide UCB

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Unduh Selebaran informasi (PIL)
25-01-2023
Unduh Karakteristik produk (SPC)
25-01-2023

Bahan aktif:

lacosamide

Tersedia dari:

UCB Pharma S.A.

Kode ATC:

N03AX18

INN (Nama Internasional):

lacosamide

Kelompok Terapi:

Antiepileptics,

Area terapi:

Epilepsies, Partial

Indikasi Terapi:

Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.,

Ringkasan produk:

Revision: 6

Status otorisasi:

Authorised

Tanggal Otorisasi:

2019-08-26

Selebaran informasi

                                121
B. PACKAGE LEAFLET
122
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
LACOSAMIDE UCB 50 MG FILM-COATED TABLETS
LACOSAMIDE UCB 100 MG FILM-COATED TABLETS
LACOSAMIDE UCB 150 MG FILM-COATED TABLETS
LACOSAMIDE UCB 200 MG FILM-COATED TABLETS
lacosamide
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Lacosamide UCB is and what it is used for
2.
What you need to know before you take Lacosamide UCB
3.
How to take Lacosamide UCB
4.
Possible side effects
5.
How to store Lacosamide UCB
6.
Contents of the pack and other information
1.
WHAT LACOSAMIDE UCB IS AND WHAT IT IS USED FOR
WHAT LACOSAMIDE UCB IS
Lacosamide UCB contains lacosamide. This belongs to a group of
medicines called “antiepileptic
medicines”. These medicines are used to treat epilepsy.
•
You have been given this medicine to lower the number of fits
(seizures) you have.
WHAT LACOSAMIDE UCB IS USED FOR
•
Lacosamide UCB is used:
•
on its own and in association with other antiepileptic medicines in
adults, adolescents
and children aged 2 years and older to treat a certain type of
epilepsy characterised by
the occurrence of partial-onset seizure with or without secondary
generalisation. In
this type of epilepsy, fits first affect only one side of your brain.
However, these may
then spread to larger areas on both sides of your brain;
•
in association with other antiepileptic medicines in adults,
adolescents and children
aged 4 year and older to treat primary generalised tonic-clonic
seizures (major fits,
including loss of con
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Lacosamide UCB 50 mg film-coated tablets
Lacosamide UCB 100 mg film-coated tablets
Lacosamide UCB 150 mg film-coated tablets
Lacosamide UCB 200 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Lacosamide UCB 50 mg film-coated tablets
Each film-coated tablet contains 50 mg lacosamide.
Lacosamide UCB 100 mg film-coated tablets
Each film-coated tablet contains 100 mg lacosamide.
Lacosamide UCB 150 mg film-coated tablets
Each film-coated tablet contains 150 mg lacosamide.
Lacosamide UCB 200 mg film-coated tablets
Each film-coated tablet contains 200 mg lacosamide.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet
Lacosamide UCB 50 mg film-coated tablets
Pinkish, oval film-coated tablets with approximate dimensions of 10.4
mm x 4.9 mm, and debossed
with ‘SP’ on one side and ‘50’ on the other side.
Lacosamide UCB 100 mg film-coated tablets
Dark yellow, oval film-coated tablets with approximate dimensions of
13.2 mm x 6.1 mm, and
debossed with ‘SP’ on one side and ‘100’ on the other side.
Lacosamide UCB 150 mg film-coated tablets
Salmon, oval film-coated tablets with approximate dimensions of 15.1
mm x 7.0 mm, and debossed
with ‘SP’ on one side and ‘150’ on the other side.
Lacosamide UCB 200 mg film-coated tablets
Blue, oval film-coated tablets with approximate dimensions of 16.6 mm
x 7.8 mm, and debossed with
‘SP’ on one side and ‘200’ on the other side.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Lacosamide UCB is indicated as monotherapy in the treatment of
partial-onset seizures with or
without secondary generalisation in adults, adolescents and children
from 2 years of age with epilepsy.
Lacosamide UCB is indicated as adjunctive therapy
3
•
in the treatment of partial-onset seizures with or without secondary
generalisation in adults,
adolescents and children from 2 years of age with epilepsy.
•
in the treatment of primary generalised 
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 25-01-2023
Karakteristik produk Karakteristik produk Bulgar 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 25-03-2024
Selebaran informasi Selebaran informasi Spanyol 25-01-2023
Karakteristik produk Karakteristik produk Spanyol 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 25-03-2024
Selebaran informasi Selebaran informasi Cheska 25-01-2023
Karakteristik produk Karakteristik produk Cheska 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 25-03-2024
Selebaran informasi Selebaran informasi Dansk 25-01-2023
Karakteristik produk Karakteristik produk Dansk 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 25-03-2024
Selebaran informasi Selebaran informasi Jerman 25-01-2023
Karakteristik produk Karakteristik produk Jerman 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 25-03-2024
Selebaran informasi Selebaran informasi Esti 25-01-2023
Karakteristik produk Karakteristik produk Esti 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 25-03-2024
Selebaran informasi Selebaran informasi Yunani 25-01-2023
Karakteristik produk Karakteristik produk Yunani 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 25-03-2024
Selebaran informasi Selebaran informasi Prancis 25-01-2023
Karakteristik produk Karakteristik produk Prancis 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 25-03-2024
Selebaran informasi Selebaran informasi Italia 25-01-2023
Karakteristik produk Karakteristik produk Italia 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 25-03-2024
Selebaran informasi Selebaran informasi Latvi 25-01-2023
Karakteristik produk Karakteristik produk Latvi 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 25-03-2024
Selebaran informasi Selebaran informasi Lituavi 25-01-2023
Karakteristik produk Karakteristik produk Lituavi 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 25-03-2024
Selebaran informasi Selebaran informasi Hungaria 25-01-2023
Karakteristik produk Karakteristik produk Hungaria 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 25-03-2024
Selebaran informasi Selebaran informasi Malta 25-01-2023
Karakteristik produk Karakteristik produk Malta 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 25-03-2024
Selebaran informasi Selebaran informasi Belanda 25-01-2023
Karakteristik produk Karakteristik produk Belanda 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 25-03-2024
Selebaran informasi Selebaran informasi Polski 25-01-2023
Karakteristik produk Karakteristik produk Polski 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 25-03-2024
Selebaran informasi Selebaran informasi Portugis 25-01-2023
Karakteristik produk Karakteristik produk Portugis 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 25-03-2024
Selebaran informasi Selebaran informasi Rumania 25-01-2023
Karakteristik produk Karakteristik produk Rumania 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 25-03-2024
Selebaran informasi Selebaran informasi Slovak 25-01-2023
Karakteristik produk Karakteristik produk Slovak 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 25-03-2024
Selebaran informasi Selebaran informasi Sloven 25-01-2023
Karakteristik produk Karakteristik produk Sloven 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 25-03-2024
Selebaran informasi Selebaran informasi Suomi 25-01-2023
Karakteristik produk Karakteristik produk Suomi 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 25-03-2024
Selebaran informasi Selebaran informasi Swedia 25-01-2023
Karakteristik produk Karakteristik produk Swedia 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 25-03-2024
Selebaran informasi Selebaran informasi Norwegia 25-01-2023
Karakteristik produk Karakteristik produk Norwegia 25-01-2023
Selebaran informasi Selebaran informasi Islandia 25-01-2023
Karakteristik produk Karakteristik produk Islandia 25-01-2023
Selebaran informasi Selebaran informasi Kroasia 25-01-2023
Karakteristik produk Karakteristik produk Kroasia 25-01-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 25-03-2024

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen